Stratifying malignant mesothelioma patients in “low” and “high” syndecan-1 level using a cutoff of 100.2 ng/mL resulted in median survival times of 17.0 and 7.8 months, respectively (hazard ratio 2.77, 95% CI 1.35 to 5.68; Figure 4). Here, SDC1 is linked to malignant mesothelioma.